Speciality: Surgery
Description:
Welcome to our podcast. Today, we're exploring when surgery is the best treatment option. Surgery is often considered when less invasive treatments, like medication or physical therapy, aren’t effective, or if a condition poses serious risks to your health. For example, certain cancers, severe injuries, or organ problems may require surgical intervention. Your doctor will weigh factors such as your overall health, the potential benefits, and possible risks before recommending surgery. Remember, seeking a second opinion and asking questions is always encouraged. By understanding your options, you can make informed decisions that are right for you. Thanks for listening to our quick guide on when surgery might be the best choice.
See More Webinars @ Hidoc Webinars
1.
New surgical method shows promising results for cervical cancer treatment
2.
Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth
3.
GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium
4.
Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer
5.
Can Prior Authorization Be Better With Artificial Intelligence?
1.
Checkpoint Inhibitors in Oncology: Advances in PD-1/PD-L1 and CTLA-4 Targeted Therapy
2.
Public Health Strategies for Improving Cancer Survivorship Support Systems
3.
Analyzing the Mechanisms and Efficacy of Carboplatin, Abraxane, and Albumin-Bound Formulations
4.
Treating Methemoglobinemia: What You Need to Know Now!
5.
Red Cell Deformability as a Target in Critical Illness
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
2.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
5.
Updates on Standard V/S High Risk Myeloma Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation